James B. Tananbaum bought $2.5M of LTGO
director, owner at Latigo Biotherapeutics, Inc.. 140,000 shares at an average of $18.00, traded Aug 10, 2026, filed Aug 10, 2026.
Score components
- +15RoleDirector
- +25Trade size$2.5M at market
- +3Relative to holdingsHoldings up 7%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001581754-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | CConversion Common Stockindirect: See footnote | +3,117,664 | - | - | 3,117,664 | Aug 10, 2026 |
| Aug 10, 2026 | CConversion Common Stockindirect: See footnote | +445,320 | - | - | 3,562,984 | Aug 10, 2026 |
| Aug 10, 2026 | CConversion Common Stockindirect: See footnote | +1,125,823 | - | - | 1,125,823 | Aug 10, 2026 |
| Aug 10, 2026 | CConversion Common Stockindirect: See footnote | +742,201 | - | - | 1,868,024 | Aug 10, 2026 |
| Aug 10, 2026 | POpen-market purchase Common Stockindirect: See footnote | +140,000 | $18.00 | $2.5M | 2,008,024 | Aug 10, 2026 |
| Aug 10, 2026 | CConversion Common Stockindirect: See footnote | +195,776 | - | - | 2,203,800 | Aug 10, 2026 |
| Aug 10, 2026 | CConversion Common Stockindirect: See footnote | +3,117,664 | - | - | 3,117,664 | Aug 10, 2026 |
| Aug 10, 2026 | CConversion Common Stockindirect: See footnote | +296,880 | - | - | 3,414,544 | Aug 10, 2026 |
| Aug 10, 2026 | CConversion Series A-2 Convertible Stockderivativeindirect: See footnote | -3,117,664 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -445,320 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See footnote | -1,125,823 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -742,201 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See footnote | -3,117,664 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -296,880 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | CConversion Convertible Promissory Notederivativeindirect: See footnote | -195,776 | - | - | 0 | Aug 10, 2026 |
Related signals
Other insiders at Latigo Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | $2.5M 140,000 shares | +7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.